Noticias y vídeos - GUERBET - Inglés

Guerbet Guerbet: Change in Guerbet’s Board of Directors. 20-March-2024 / 18:00 CET/CEST Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. Change in Guerbet’s Board of Directors Villepinte, 20 March 2024 : Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, today appointed Hugues Lecat as “Censeur” (non-voting director) with immediate effect. Hugues...

Guerbet Guerbet: 2023 full-year results. 20-March-2024 / 17:45 CET/CEST Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. 2023 full-year results Solid business growth Full-year revenue: €785.7m, up 5.9% on a like-for-like basis and at CER [1] , in line with the announced target (> 5%) Strong momentum in Asia (+15.9% at CER) and EMEA (+6.0%), and stable sales in the Americas (-1.4%) thanks to strong...

Guerbet Guerbet strengthens its Executive Committee with two new appointments to consolidate its medium and long-term ambitions. 11-March-2024 / 08:00 CET/CEST Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. Guerbet strengthens its Executive Committee with two new appointments to consolidate its medium and long-term ambitions Christine Allard, S VP Public Affairs and Corporate Communications Eva Ohlsson,...

Guerbet Guerbet: 2023 revenue 08-Feb-2024 / 17:45 CET/CEST Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. 2023 revenue Activity Annual revenue: €785.7m, up 6.4% at CER [1] and 5.9% like-for-like [2] and at CER, in line with the announced target (> 5%). Sharp acceleration in growth in the 4 th quarter (+17.9% at CER), driven by the performance of the Americas region, at +39% 2023 profitability The...

Guerbet Guerbet: Death of Michel Guerbet, son of the founder and company director for over 30 years. 30-Jan-2024 / 17:45 CET/CEST Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. Death of Michel Guerbet, son of the founder and company director for over 30 years Villepinte, 30 January 2024 The Group is deeply saddened to announce the death of Michel Guerbet, who passed away on January 23, 2024 at the age of...

The CHMP issues an opinion in favour of granting an EU marketing authorisation for Elucirem™ (Gadopiclenol) with the indication of use for magnetic resonance imaging with contrast enhancement in adults and children aged 2 years and over If approved by the European Commission, Elucirem™ (Gadopiclenol) will mark a step forward in innovation in MRI contrast media, thus answering to the Health authorities recommendation and concerns of patients and radiologists in Europe. An MRI exam with...

Half-year results 2023 Acceleration of activity Half-year revenue: €378.6 million, up 2.8% at CER 1 Strong acceleration of activity in the second quarter, up 6.7% at CER Profitability in line with expectations EBITDA for the first half-year: €45.9 million, compared to €50.5 million one year earlier The restated EBITDA margin 2 amounted to 12.7% of revenue 2023 objectives confirmed Revenue: expected growth of more than 5% on a like-for-like basis and at CER Expected restated EBITDA margin2...

Guerbet wins PI-CAI Grand Challenge on detection of prostate cancer Villepinte, 17 July 2023 : Guerbet (FR0000032526 GBT), a global specialist in contrast media and medical imaging solutions, is delighted to announce the success of its teams at the PI-CAI (Prostate Imaging: Cancer Al) Grand Challenge 1 , an international challenge organised by a consortium 2 of radiology opinion leaders in prostate imaging, urologists and artificial intelligence experts, to compare the performance of artificial...

Guerbet strengthens its Executive Committee with two new appointments to accelerate its commercial and industrial development Dan Raffi appointed Director of Commercial Operations Raoul Bernhardt appointed Director of Industrial Operations Villepinte, 10 July 2023 : Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, announces the strengthening of its management team with two appointments. Dan Raffi and Raoul Bernhardt have joined the Group as...

2022 annual results Activity Annual revenue: €753.3 million, up 2.9% (-1.1% at CER 1 ) Steady momentum in Asia and for Interventional Imaging; negative impact of production delays at the Raleigh site Profitability in line with expectations The restated EBITDA margin 2 is 13.8%, at the top of the range of 13% to 14% announced last October 2023 outlook Revenue: expected growth above 5% on a like-for-like basis and at CER 1 Restated EBITDA margin 3 expected around 11% before returning in 2024 to...

2022 revenue Activity Annual revenue: €753.3 million, up +2.9% (-1.1% at CER 1 ); production lags at the Raleigh site weighed on activity Profitability 2022 EBITDA margin: confirmation of the announced range of 13% to 14% (excluding extraordinary costs for the optimization of the operational structure and changes in the sales model in China) Outlook 2023 revenue: expected growth above 5% on a like-for-like basis and at CER Villepinte, February 9, 2023 : Guerbet (FR0000032526 GBT), a global...

2023 Strategic Priorities Diagnostic Imaging : increase Elucirem TM sales and strengthen international positions Interventional Imaging : prioritise Lipiodol sales with the development of innovative indications Artificial Intelligence: execution of the roadmap for the emergence of a major AI player dedicated to medical imaging in oncology Villepinte, 16 January 2023: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging has announced its strategic...

Intrasense opens its share capital to the Guerbet Group, which announces its intent to file a voluntary tender offer under the same price conditions Montpellier, France, January 11, 2023 at 6:00 PM CET Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions ("Intrasense" or the "Company") announces that the Guerbet Group (FR0000032526 - GBT) has acquired a 39% stake in its share capital through a reserved share capital increase for a total amount of 8.8 million...

Guerbet Guerbet: Intrasense opens its share capital to the Guerbet Group, which announces its intent to file a voluntary tender offer under the same price conditions 11-Jan-2023 / 18:23 CET/CEST Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. Intrasense opens its share capital to the Guerbet Group, which announces its intent to file a voluntary tender offer under the same price conditions Montpellier,...

Guerbet to Spotlight the Novel New Drug Elucirem™ (gadopiclenol) injection at the 2022 Radiological Society of North America Scientific Assembly and Annual Meeting PR Newswire PRINCETON, N.J., Nov. 22, 2022 Join us at Booth #1711 Opportunity to learn about the recently US FDA-approved novel new drug, Elucirem™ Announcing Guerbet Research Scholar Grant in Partnership with RSNA Displaying a portfolio of digital and artificial intelligence software solutions to enhance patients' experience...

Guerbet announces a change in governance for its Artificial Intelligence p rojects Villepinte, November 3rd , 2022: Guerbet today announced an agreement with Merative , formalizing the termination of the ir collaboration signed in July 2018. Guerbet today announced an agreement with Merative formalizing the termination of their collaboration initiated in July 2018. This partnership aimed to design, develop and market software solutions to help diagnose and monitor liver and prostate cancers. The...

Revenue on September 30, 2022 Faster growth in Q3 2022 Revenue: +5.1% at CER 1 (€187 million) Very dynamic activity in Asia (+18.4%) and within MRI (+17.3%) Cumulative revenue at 9 months: +0.8% at CER (€569.2 million) Update of 2022 financial targets Impact of prioritizing Elucirem TM production at the Raleigh plant Like-for-like revenue growth below 2% at CER, 2022 EBITDA margin between 13% and 14% (excluding extraordinary costs to optimize the operating structure and change the sales...

Guerbet obtains one million euros of public funding from Bpifrance (France 2030 investment plan) for a project developing artificial intelligence for the early detection of pancreatic cancer Villepinte, 26 September 2022 – 18:00 : Guerbet (GBT) obtains one million euros of public funding through a call for projects concerning the acceleration strategy in digital health via the France 2030 investment plan. The early diagnosis of pancreatic cancer is a major public health concern. The...

Guerbet announces U.S. Food and Drug Administration (FDA) approval of Elucirem™ (Gadopiclenol) FDA approval of Elucirem TM (NDA 216986) was granted after priority review, a designation assigned to applications for drugs that provide significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions compared to available therapies. In the approved indications, a contrast-enhanced MRI examination using Elucirem™ requires half the gadolinium...

Q1 2022 sales Business growth Sales Increase of 2.7% compared with Q1 2021 (€181.1m) Up 0.5% at constant exchange rates (CER 1 ) 2022 guidance confirmed Villepinte, Thursday, April 21, 2022 – Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, reports its revenue for first-quarter 2022. As of 31 st of March, revenue totaled €181.1 million, up 2.7% from first-quarter 2021 (€176.3 million). This growth in business activity includes a...